肺动脉高压大品种遭围猎!豪森、朱养心首仿同日获批,强生能否保持增速?

医药经济报
19 Dec 2024

在国内市场,大品种进口药首仿品种一旦获批,“专利悬崖”效应将极大加剧市场竞争,激烈的价格战也将不可避免。日前,国家药品监督管理局政务服务门户网站信息显示,江苏豪森药业集团有限公司、杭州朱养心药业有限公司以仿制4类报产的司来帕格片同日获批上市,并列国内首仿+首家过评。值得关注的是,司来帕格原研进口药是一款由爱可泰隆研发的前列腺素I2(PGI2)受体激动剂,于2015年12月首次在美国获批上市,商品...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10